Key result
CALM1/2 variants affect ~5% of children with suspected inherited arrhythmias, linked to severe early-onset phenotypes.
Why the study?
Cardiac calmodulinopathy is extremely rare, caused by variants in CALM1, CALM2, or CALM3, and characterized by life-threatening arrhythmias and sudden death in the young.
Observational (n=195)
Yes
Calmodulinopathy accounts for 5% of symptomatic inherited arrhythmias in Japanese children and is associated with severe, early-onset cardiac phenotypes requiring prompt diagnosis and treatment.
BACKGROUND: Cardiac calmodulinopathy, characterized by a life-threatening arrhythmia and sudden death in the young, is extremely rare and caused by genes encoding calmodulin, namely calmodulin 1 (CALM1), CALM2, and CALM3. METHODS AND RESULTS: We screened 195 symptomatic children (age 0-12 years) who were suspected of inherited arrhythmias for 48 candidate genes, using a next-generation sequencer. Ten probands were identified as carrying variants in any of CALM1-3 (5%; median age 5 years), who were initially diagnosed with long QT syndrome (LQTS; n=5), catecholaminergic polymorphic ventricular tachycardia (CPVT; n=3), and overlap syndrome (n=2). Two probands harbored a CALM1 variant and 8 probands harbored 6 CALM2 variants. There were 4 clinical phenotypes: (1) documented lethal arrhythmic events (LAEs): 4 carriers of N98S in CALM1 or CALM2; (2) suspected LAEs: CALM2 p.D96G and D132G carriers experienced syncope and transient cardiopulmonary arrest under emotional stimulation; (3) critical cardiac complication: CALM2 p.D96V and p.E141K carriers showed severe cardiac dysfunction with QTc prolongation; and (4) neurological and developmental disorders: 2 carriers of CALM2 p.E46K showed cardiac phenotypes of CPVT. Beta-blocker therapy was effective in all cases except cardiac dysfunction, especially in combination with flecainide (CPVT-like phenotype) and mexiletine (LQTS-like). CONCLUSIONS: Calmodulinopathy patients presented severe cardiac features, and their onset of LAEs was earlier in life, requiring diagnosis and treatment at the earliest age possible.
No takes yet. Share an insight, caveat, or question.
Fukuyama et al. (2023) conducted an observational in Inherited primary arrhythmia syndrome (IPAS) (n=195). CALM1, CALM2, and CALM3 gene variants vs. Non-carriers was evaluated on Prevalence of CALM variants and characterization of clinical phenotypes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: